Therapeutic interventions of tissue specific autoimmune onset in systemic lupus erythematosus

Mini-Reviews in Medicinal Chemistry

Volumn 17, Issue 15, 2017, Pages 1418-1424

  Dasgupta, Subhajit ^a   Dasgupta, Shaoni ^b  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

^b Academic Magnet High School   (United States)

Author keywords

Autoimmune disease; B cell; ER alpha; Lupus; Monoclonal antibody; NF kappa B

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID;

ANIMAL; DRUG DEVELOPMENT; FEMALE; HUMAN; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ADRENAL CORTEX HORMONES; ANIMALS; CYCLOPHOSPHAMIDE; DRUG DISCOVERY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID;

EID: 85031422180     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557517666170725142739     Document Type: Review

References (97)

1. Tedeschi, S.K.; Bermas, B.; Costenbader, K.H. Sexual disparities in the incidence and course of SLE and RA. Clin. Immunol., 2013, 149(2), 211-218.
2. Hiraki, L.T.; Feldman, C.H.; Liu, J.; Alarcon, G.S.; Fischer, M.A.; Winkelmayer, W.C.; Costenbader, K.H. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis Rheum., 2012, 64(8), 2669-2676.
3. Furst, D.E.; Clarke, A.E.; Fernandes, A.W.; Bancroft, T.; Greth, W.; Iorga, S.R. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. Lupus, 22(1), 99-105.
4. Feldman, C.H.; Hiraki, L.T.; Liu, J.; Fischer, M.A.; Solomon, D.H.; Alarcon, G.S.; Winkelmayer, W.C.; Costenbader, K.H. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum., 2013, 65(3), 753-763.
5. Petri, M. Epidemiology of systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol., 2002, 16(5), 847-848.
6. Danchenko, N.; Satia, J.A.; Anthony, M.S. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus, 2006, 15(5), 308-318.
7. Cravioto, M.D.; Durand-Carbajal, M.; Jimenez-Santana, L.; Lara-Reyes, P.; Seuc, A.H.; Sanchez-Guerrero, J. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial. Arthritis Care Res. (Hoboken), 2011, 65(12), 1654-1663.
8. Yacoub Wasef S.Z. Gender differences in systemic lupus erythematosus. Gend. Med., 2004, 1(1), 12-17.
9. Lim, S.S.; Bayakly, A.R.; Helmick, C.G.; Gordon, C.; Easley, K.A. Drenkard C. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheumatol., 2014, 66(2), 357-358.
10. McCarty, D.J.; Manzi, S.; Medsger, T.A.Jr.; Ramsey-Goldman, R.; LaPorte, R.E.; Kwoh, C.K. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum., 1995, 55(9), 1260-1270.
11. Gomez-Rubio, V.; Lopez-Quilez, A. Statistical methods for the geographical analysis of rare diseases. Adv. Exp. Med. Biol., 2010, 686, 151-171.
12. Kosaraju, K.; Shenoy, S.; Suchithra, U. A cross-sectional hospital-based study of autoantibody profile and clinical manifestations of systemic lupus erythematosus in south Indian patients. Indian J. Med. Microbiol., 2010, 28(3), 245-247.
13. Werth, V.P. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun. Rev., 2005, 4(5), 296-302.
14. Tan, Y.; Yu F.; Liu G. Diverse vascular lesions in systemic lupus erythematosus and clinical implications. Curr. Opin. Nephrol. Hypertens, 2014, 25(3), 218-223.
15. Heinlen, L.D.; McClain, M.T.; Merrill, J.; Akbarali, Y.W.; Edgerton, C.C.; Harley, J.B.; James J.A. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum., 2007, 56(7), 2344-2351.
16. Meszaros, Z.S.; Perl, A.; Faraone, S.V. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J. Clin. Psychiatry, 2012, 75(7), 993-1001.
17. Sanna, G.; Bertolaccini, M.L.; Cuadrado, M.J.; Laing, H.; Khamashta, M.A.; Mathieu, A.; Hughes, G.R. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol., 2003, 50(5), 985-992.
18. Leffler, J.; Bengtsson, A.A.; Blom, A.M. The complement system in systemic lupus erythematosus: an update. Ann. Rheum. Dis., 2014, 75(9), 1601-1606.
19. Lech, M.; Anders, H.J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol, 2013, 24(9), 1357-1366.
20. Papp, K.; Vegh, P.; Hobor, R.; Szittner, Z.; Voko, Z.; Podani, J.; Czirjak, L.; Prechl, J. Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein binding analysis on antigen microarrays. PLoS One, 2012, 7(9), e44824.
21. Hanrotel-Saliou, C.; Segalen, I.; Le, Meur, Y.; Youinou, P.; Renaudineau, Y. Glomerular antibodies in lupus nephritis. Clin. Rev. Allergy Immunol., 2011, 40(3), 151-158.
22. van Bruggen, M.C.; Kramers, C.; Walgreen, B.; Elema, J.D.; Kallenberg, C.G.; van den Born, J.; Smeenk, R. J.; Assmann, K. J.; Muller, S.; Monestier, M.; Berden, J.H. Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol. Dial. Transplant, 1997, 12(1), 57-66.
23. Dema, B.; Charles, N. Advances in mechanisms of systemic lupus erythematosus. Discov. Med., 2014, 17(95), 247-255.
24. Doria, A.; Gatto, M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus, 2012, 21(14), 1492-1496.
25. Ishimoto, T.; Cara-Fuentes, G.; Wang, H.; Shimada, M.; Wasserfall, H.; Winter, W.E.; Rivard, C.J.; Araya, C.E.; Saleem M.A.; Mathieson, P.W.; Johnson, R. J.; Garin, E. H. Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes. Pediatr. Nephrol., 2013, 28(9), 1803-1812.
26. Glassock, R.J. Pathogenesis of membranous nephropathy: a new paradigm in evolution. Contrib. Nephrol., 2013, 181, 131-132.
27. Makker, S.P.; Tramontano, A. Idiopathic membranous nephropathy: An autoimmune disease. Semin. Nephrol., 2011, 51(4), 333-340.
28. Kanapathippillai, P.; Hedberg, A.; Fenton, C.G.; Fenton, K.A. Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis. Cytokine, 62(2), 244-252.
29. Yung, S.; Cheung, K.F; Zhang, Q; Chan, T.M. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J. Am. Soc. Nephrol., 2010, 21(11), 1912-1927.
30. Dasgupta, S; Eudaly, J. Estrogen receptor-alpha mediates Toll-like receptor-2 agonist-induced monocyte chemoattractant protein-1 production in mesangial cells. Results Immunol., 2012, 2, 196-193.
31. Zhao, J.; Zhang, H.; Huang, Y.; Wang, H.; Wang, S.; Zhao, C.; Liang, Y.; Yang, N. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kappaB activation. Intl. Immunopharmacol., 2013, 17(1), 116-122.
32. Yougbare, I.; Boire, G.; Roy, M.; Lugnier, C.; Rouseau, E. NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-kappaB signalling pathways while reducing proinflammatory cytokine production. Can J. Physiol Pharmacol., 2013, 91(5), 353-361.
33. Yoon, H.Y.; Lee, E.G.; Lee, H.; Cho, I.J.; Choi, Y.J.; Sung, M.S.; Yoo, H.G.; Yoo, W.H. Kaempferol inhibits IL-1beta-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX-2, PGE2 and MMPs. Intl. J. Mol Med., 2013, 52(4), 971-977.
34. Sehnert, B.; Burkhardt, H.; Wessels, J.T.; Schroder, A.; May, M.J.; Vestweber, D.; Zwerina, J.; Warnatz, K.; Nimmerjahn, F.; Schett, G.; Dubel, S.; Voll, R.E. NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc. Natl. Acad. Sci. USA, 2013, 110(41), 16556-16561.
35. Dasgupta, S.; Jana, M.; Zhou, Y.; Fung, Y.K.; Ghosh, S.; Pahan, K. Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J. Immunol., 2004, 175(2), 1344-1354.
36. Yan, J.; Greer, J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets, 2008, 7(6), 536-557.
37. Erikson, J.; Mandik, L.; Bui, A.; Eaton, A.; Noorchashm, H.; Nguyen, K.A.; Roark, J.H. Self-reactive B cells in nonautoimmune and autoimmune mice. Immunol. Res., 1998, 17(1-2), 49-61.
38. Chan, O.T.; Madaio, M.P.; Shlomchik, M.J. The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev., 1999, 169, 107-121.
39. Perera, J.; Meng, L.; Meng, F.; Huang, H. Autoreactive thymic B cells are efficient antigen-presenting cells of cognate self-antigens for T cell negative selection. Proc. Natl. Acad. Sci. USA, 2013, 110(42), 17011-17016.
40. Vincent, F.B.; Morand, E.F.; Schneider, P.; Mackay, F. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol., 10(6), 365-373.
41. Vincent, F.B.; Morand, E.F.; Mackay, F. BAFF and innate immunity: New therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol., 2012, 90(3), 293-303.
42. Engler, J.B.; Undeutsch, R.; Kloke, L.; Rosenberger, S.; Backhaus, M.; Schneider, U.; Egerer, K.; Dragun, D.; Hofmann, J.; Huscher, D.; Burmester, G.R.; Humrich, J.Y.; Enghard, P.; Riemekasten, G. Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. Ann. Rheum. Dis., 2011, 70(12), 2176-2183.
43. Bonelli, M.; Savitskaya, A.; von Dalwigk, K.; Steiner, C.W.; Aletaha, D.; Smolen, J.S.; Scheinecker, C. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Intl. Immunol., 2008, 20(7), 861-868.
44. Robak, E.; Smolewski, P.; Wozniacka, A.; Sysa-Jedrzejowska, A.; Robak, T. Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus. Mediators Inflamm., 15(3), 171-180.
45. Kis-Toth, K.; Tsokos, G.C. Dendritic cell function in lupus: Independent contributors or victims of aberrant immune regulation. Autoimmunity, 2010, 45(2), 121-130.
46. Scheinecker, C.; Zwolfer, B.; Koller, M.; Manner, G.; Smolen, J.S. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum., 2001, 44(4), 856-865.
47. Khan, S.A.; Nowatzky, J.; Jimenez-Branda, S.; Greenberg, J.D.; Clancy, R.; Buyon, J.; Bhardwaj N. Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. Exp. Mol. Pathol., 2013, 95(2), 121-123.
48. Lan, Q.; Zhou, X.; Fan, H.; Chen, M.; Wang, J.; Ryffel, B.; Brand, D.; Ramalingam, R.; Kiela, P. R.; Horwitz, D.; Liu, Z.; Zheng, S.G. Polyclonal CD4+Foxp3+ Treg cells induce TGFbeta-dependent tolerogenic dendritic cells that suppress the murine lupus-like syndrome. J. Mol Cell Biol., 2012, 4(6), 409-419.
49. Qiu, F.; Song, L.; Yang, N.; Li, X. Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus, 2013, 22(10), 1011-1016.
50. Song, L.; Qiu, F.; Fan, Y.; Ding, F.; Liu, H.; Shu, Q. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J. Clin. Immunol., 2013, 33(1), 111-117.
51. Flanc, R.S.; Roberts, M.A.; Strippoli, G.F.; Chadban, S.J.; Kerr, P.G.; Atkins, R.C. Treatment for lupus nephritis. Cochrane Database Sys. Rev., 2004, 1, CD002922.
52. Mok, C.C.; Yap, D.Y.; Navarra, S.V.; Liu, Z.H.; Zhao, M.H.; Lu, L.; Takeuchi, T.; Avihingsanon, Y.; Yu, X.Q.; Lugue-Lizardo, L.R.; Sumethkul, V.; Shen, N.; Chen, S.L.; Chan, T. M. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton), 2014, 19(1), 11-20.
53. Roccatello, D.; Sciascia, S.; Rossi, D.; Alpa, M.; Naretto, C.; Baldovino, S.; Menegatti, E.; La Grotta, R.; Modena, V. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant, 2011, 26(12), 3987-3992.
54. Sundel, R.; Solomons, N.; Lisk, L. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus, 2012, 21(13), 1433-1443.
55. Ong, L.M.; Hooi, L.S.; Lim, T.O.; Goh, B.L.; Ahmad, G.; Ghazalli, R.; Teo, S.M.; Wong, H.S.; Tan, S.Y.; Shaariah, W.; Tan, C.C.; Morad, Z. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton), 2005, 10(5), 504-510.
56. Bulkley, B.H.; Roberts, W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am. J. Med., 1975, 58(2), 243-244.
57. Zonana-Nacach, A.; Barr, S.G.; Magder, L.S.; Petri, M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum., 2000, 43(8), 1801-1808.
58. Ruiz-Arruza, I.; Ugarte, A.; Cabezas-Rodriguez, I.; Medina, J.A.; Moran, M.A.; Ruiz-Irastorza, G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford), 2014, 53(8), 1470-1476.
59. Hughes, G.C.; Choubey, D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat. Rev. Rheumatol., 10(12), 740-751.
60. Hughes, G.C. Progesterone and autoimmune disease. Autoimmun. Rev., 2011, 11(6-7), A502-514.
61. Wolkowitz, O.M.; Reus, V.I.; Canick, J.; Levin, B., Lupien, S. Glucocorticoid medication, memory and steroid psychosis in medical illness. Ann. N.Y. AcadSci., 1997, 823, 81-96.
62. Kanik, K.S.; Wilder, R.L. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy. Rheum Dis. Clin. North Am., 2000, 26(4), 805-23.
63. Keith, J.C. Jr.; Albert, L.M; Leathurby, Y.; Follettie, M.; Wang, L.; Borges-Marcucci, L.; Chadwick, C.C.; Steffan, R.J.; Harnish, D.C. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res. Ther., 2005, 7(3), R427-438.
64. Cobo-Ibanez, T.; Loza-Santamaria, E.; Pego-Reigosa, J. M.; Marques, A. O.; Rua-Figueroa, I.; Fernandez-Nebro, A.; Caliz, R.; Lopez Longo, F. J.; Munoz-Fernandez, S. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. Semin. Arthritis Rheum., 2014 pii, S0049-0172(14)00050-X. doi, 10.1016/j.semarthrit. 2014.04.002.
65. Marinaki, S.; Skalioti, C.; Boletis, J.N., B cell depletion: rituximab in glomerular disease and transplantation. Nephron. Extra, 2013, 3(1), 125-130.
66. Gonzalez-Echavarri, C.; Pernas, B.; Ugarte, A.; Ruiz-Irastorza, G. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. Lupus, 2014, 23(3), 323-326.
67. Maloney, D.G.; Grillo-Lopez, A.J.; White, C.A.; Bodkin, D.; Schilder, R.J.; Neidhart, J.A. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood, 1997, 90(6), 2188-2195.
68. Piro, L.D.; White, C.A.; Grillo-Lopez, A.J.; Janakiraman, N.; Saven, A.; Beck, T.M. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann. Oncol., 1999, 10(6), 655-661.
69. Cross, A.H.; Klein, R.S.; Piccio, L. Rituximab combination therapy in relapsing multiple sclerosis. Ther. Adv. Neurol. Disord., 2012, 5(6), 311-319.
70. Naismith, R.T.; Piccio, L.; Lyons, J.A; Lauber, J.; Tutlam, N.T.; Parks, B.J. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology, 2010, 74(23), 1860-1867.
71. Maeshima, K.; Ishii, K.; Torigoe, M.; Imada, C.; Iwakura, M.; Hamasaki, H.; Yoshimatsu, H. Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. Lupus 2012, 21(9), 1003-1006.
72. Ternant, D.; Bejan-Angoulvant, T.; Passot, C.; Mulleman, D.; Paintaud, G., Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. Clin. Pharmacokinet., 2015, 10.1007/s40262-015-0296-9.
73. Narvaez, J.; Rios-Rodriguez, V.; de la Fuente, D.; Estrada, P.; Lopez-Vives, L.; Gomez-Vaquero, C. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin. Arthritis Rheum., 2011, 41(3), 364-372.
74. Tokunaga, M.; Saito, K.; Kawabata, D.; Imura, Y.; Fujii, T.; Nakayamada, S.; Tsujimura, S.; Nawata, M.; Iwata, S.; Azuma, T.; Mimori, T.; Tanaka, Y. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum Dis., 2007, 66(4), 470-475.
75. Fernandez-Nebro, A.; Marenco, J.L.; Lopez-Longo, F.; Galindo, M.; Hernandez-Cruz, B.E.; Narvaez, J.; Rua-Figueroa, I.; Raya-Alvarez, E.; Zea, A.; Freire, M.; Sanchez-Atrio, A.I.; Garcia-Vicuna, R; Pego-Reigosa, J.M.; Manrique-Arija, S.; Nieves-Martin, L.; Carreno, L. The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). Lupus, 2014, 23(10), 1014-1022.
76. Harvey, P.R.; Gordon, C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs, 2013, 27(2), 85-95.
77. Manzi, S.; Sanchez-Guerrero, J.; Merrill, J.T.; Furie, R.; Gladman, D; Navarra, S.V. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann. Rheum Dis., 2012, 71(11), 1833-1838.
78. Vincent, F.B.; Saulep-Easton, D.; Figgett, W.A.; Fairfax, K.A.; Mackay, F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev., 2013, 24(3), 203-215.
79. Anolik, J.H.; Aringer, M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol., 19(5), 859-878.
80. Dorner, T.; Goldenberg, D.M. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther. Clin. Risk Manag., 3(5), 953-959.
81. Stein, R.; Qu, Z.; Chen, S.; Rosario, A.; Shi, V.; Hayes, M.; Horak, I. D.; Hansen, H. J.; Goldenberg, D. M. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin. Cancer Res., 2004, 10(8), 2868-2878.
82. Zheng, X.; Vladau, C.; Zhang, X.; Suzuki, M.; Ichim, T.E.; Zhang, Z. X. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood, 2009, 113(12), 2646-2654.
83. Nagafuchi, H.; Shimoyama, Y.; Kashiwakura, J.; Takeno, M.; Sakane, T.; Suzuki, N. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol., 2003, 21(1), 71-77.
84. Wu, Y.; Xu, J.; Shinde, S.; Grewal, I.; Henderson, T., Flavell R.A. Liu, Y. Rapid induction of a novel costimulatory activity on B cells by CD40 ligand. Curr. Biol., 1995, 5(11), 1303-1311.
85. Pascual, J.; Mezrich, J.D.; Djamali, A.; Leverson, G.; Chin, L.T.; Torrealba, J.; Bloom, D.; Voss, B.; Becker, B. N.; Knechtle, S. J.; Sollinger, H.W.; Pirsch, J.D.; Samaniego, M.D. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation, 2007, 83(11), 1429-1434.
86. Rao, S.P.; Sancho, J.; Campos-Rivera, J.; Boutin, P.M.; Severy, P.B.; Weeden, T.; Shankara, S., Roberts, B. L.; Kaplan, J. M. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One, 2012, 7(6), e39416.
87. Morales, J.; Bono, M.R.; Fierro, A.; Iniguez, R.; Zehnder, C.; Rosemblatt, M.; Calabran, L.; Herzog, C.; Benavente, D.; Aguilo, J.; Pefaur, J.; Alba, A.; Ferrario, M.; Simon, W.; Contreras, L.; Buckel, E. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. Transplant. Proc., 40(9), 3223-3228.
88. Pauklin, S.; Sernandez, I. V.; Bachmann, G.; Ramiro, A.R.; Petersen-Mahrt S.K. Estrogen directly activates AID transcription and function. J. Exp. Med., 2009, 206(1), 99-111.
89. Mai, T.; Zan, H.; Zhang, J.; Hawkins, J.S.; Xu, Z.; Casali, P. Estrogen receptors bind to and activate the HOXC4/HoxC4 promoter to potentiate HoxC4-mediated activation-induced cytosine deaminase induction, immunoglobulin class switch DNA recombination, and somatic hypermutation. J. Biol. Chem., 2010, 285(48), 37797-37810.
90. Kassi, E., Moutsatsou, P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol., 2010, 2010, 317452.
91. Grimaldi, C.M.; Michael, D.J. Diamond, B., Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J. Immunol., 2001, 167(4), 1886-1890.
92. Rider, V.; Abdou, N.I. Gender differences in autoimmunity: Molecular basis for estrogen effects in systemic lupus erythematosus. Int. Immunopharmacol., 2001, 1(6), 1009-1024.
93. Ward, J.M; Rider, V.; Abdou, N.I.; Kimler, B. Estradiol differentially regulates calreticulin: a potential link with abnormal T cell function in systemic lupus erythematosus? Lupus, 2013, 22(6), 583-586.
94. Perry, D.J.; Yin, Y.; Telarico, T.; Baker, H.V.; Dozmorov, I.; Perl, A.; Morel, L. Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor gamma. J. Immunol., 2012, 189(2), 793-803.
95. Zan, H.; Casali, P. Regulation of Aicda expression and AID activity. Autoimmunity, 2013, 46(2), 83-101.
96. Hayakawa, K.; Nakajima, S.; Hiramatsu, N.; Okamura, M.; Huang, T.; Saito, Y.; Tagawa, Y.; Tamai, M.; Takahashi, S.; Yao, J.; Kitamura, M. ER stress depresses NF-kappaB activation in mesangial cells through preferential induction of C/EBP beta. J. Am. Soc. Nephrol., 2010, 21(1), 73-81.
97. Peairs, A.; Dai, R.; Gan, L.; Shimp, S.; Rylander, M.N.; Li, L.; Reilly, C.M. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. Cell Mol. Immunol., 2010, 7(2), 123-132.